Antigens Patents (Class 435/69.3)
-
Publication number: 20120258129Abstract: The present invention is related to a M. tuberculosis fusion protein, polynucleotide coding for said protein, and a vector and host cell that contain said polynucleotide. The present invention also involves the preparation of said fusion protein, and the use thereof in preventions and treatment of tuberculosis.Type: ApplicationFiled: April 13, 2012Publication date: October 11, 2012Applicants: YANGZHOU YILIN BIOTECHNOLOGY CO., LTD, THE 309TH HOSPITAL, THE PEOPLE'S LIBERATION ARMYInventors: Xiuyun HE, Yuhui ZHUANG, Haibin WANG, Jianhua TAO
-
Patent number: 8277820Abstract: A variant of Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form of SpaA (?SpaA) in which a portion of SpaA protein is deleted for protection from Erysipelothrix rhusiopathiae infection and a process for preparing the same are provided. Introduction of amino acid substitution at a specific site in the amino acid sequence of SpaA or ?SpaA protein provides a variant of SpaA or ?SpaA protein which is immunogenic and is expressed in E. coli as inclusion bodies. The variant of SpaA or ?SpaA protein of the present invention may easily be recovered and purified since it is expressed in E. coli as inclusion bodies.Type: GrantFiled: February 8, 2005Date of Patent: October 2, 2012Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Toshihiro Ushijima, Masashi Sakaguchi, Eiji Tokunaga
-
Patent number: 8278119Abstract: By detecting an antibody which immunologically reacts with amylase ?2-A in a sample, AIP or FT1DM is examined or the possibility of developing FT1DM is determined. For instance, detection of this antibody is carried out by an immunological method using an antigen which immunologically reacts with this antibody. The antigen is preferably a partial fragment containing the amino acid sequence of amino acid numbers 299 to 511 of human amylase ?2-A (SEQ ID NO: 1).Type: GrantFiled: May 2, 2008Date of Patent: October 2, 2012Assignees: University of Yamanashi, Cosmic CorporationInventors: Tetsuro Kobayashi, Toyoshi Endo, Atsushi Sakuraoka
-
Publication number: 20120244176Abstract: It is an object of the present invention to provide a protein that can successfully treats almost all patients with cedar pollinosis and can be ingested as a food. That is, the present invention provides a protein comprising an amino acid sequence represented by SEQ ID NO:1 or comprising an amino acid sequence having a mutation(s) in said amino acid sequence, and having an immunogenicity of a cedar pollen; a polynucleotide encoding said protein; a vector comprising said polynucleotide; a transformant comprising said polynucleotide or said vector; and intended uses of said protein, said polynucleotide, and said transformant.Type: ApplicationFiled: October 28, 2010Publication date: September 27, 2012Applicants: NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES, NIPPON PAPER INDUSTRIES CO., LTD.Inventors: Fumio Takaiwa, Hidenori Takagi, Yuhya Wakasa, Yuji Fujii, Tomotaka Shinya, Saori Kasahara
-
Publication number: 20120237519Abstract: The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further relates to detection methods, vaccine therapeutics, and diagnostic methods using the PMC virus or gene/protein sequences derived therefrom.Type: ApplicationFiled: May 16, 2012Publication date: September 20, 2012Applicant: MINISTER FOR PRIMARY INDUSTRIES FOR AND ON BEHALF OF THE STATE OF NEW SOUTH WALESInventors: MELINDA JANE FROST, PETER DANIEL KIRKLAND, DEBORAH SUSAN FINLAISON
-
Publication number: 20120237538Abstract: A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium, and methods of use thereof.Type: ApplicationFiled: November 23, 2009Publication date: September 20, 2012Inventors: Evelina Angov, Elke Bergmann-Leitner, Christian Ockenhouse
-
Publication number: 20120237956Abstract: A Treponema pallidum triplet antigen construct is disclosed which includes three Treponema pallidum antigens (TP15, TP17, and TP47), as well as a ten amino acid leader sequence (tag 261) and human copper zinc superoxide dismutase (hSOD). This construct is optimized for in vitro diagnosis of syphilis infection. Plasmids containing DNA encoding the triplet antigen, host cells, production methods, detection methods, and kits are also disclosed.Type: ApplicationFiled: January 13, 2012Publication date: September 20, 2012Inventors: Jian Zheng, Renee Yura, Jianping Yang
-
Patent number: 8268966Abstract: Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.Type: GrantFiled: December 18, 2009Date of Patent: September 18, 2012Assignee: Crucell Holland B.V.Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianus Q. Bakker, Alexander Berthold Hendrik Bakker
-
Patent number: 8268322Abstract: A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.Type: GrantFiled: December 20, 2010Date of Patent: September 18, 2012Assignee: Samsung Electronics Co., Ltd.Inventors: A-yeon Cho, Min-kyung Kim, Brian Hosung Min, Jong-sang Ryu
-
Publication number: 20120231030Abstract: The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4+ epitope; and (iii) at least one CD8+ epitope. It also relates to antigen presenting cells loaded with said polypeptides, and the use thereof in immunotherapy including prevention and/or treatment of cancers or infectious diseases.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Applicants: HOPITAUX UNIVERSITAIRES DE GENEVE, UNIVERSITE DE GENEVEInventors: MADIHA SABIHA DEROUAZI, Paul R. Walker, Pierre-Yves Dietrich
-
Publication number: 20120231029Abstract: Recombinant subunit proteins derived from the MSP-1 C-terminal region of the parasite Plasmodium falciparum are described that have enhanced immunogenic properties. Selected regions of p33 have been combined with p19 to enhance the immunogenic potential of the p19 core region. As the constructs represent discontinuous segments fused to create unique proteins, the recombinant proteins expressed are not found in nature. The enhanced immunogenic potential of the disclosed recombinant proteins provided for strong, consistent and specific antibody responses. The disclosed recombinant subunit proteins are vaccine candidates for protection against infection with malaria.Type: ApplicationFiled: November 18, 2010Publication date: September 13, 2012Applicants: Hawaii Biotect Inc., University of HawaiiInventors: David E. Clements, Kae Myriam Pusic, George N.S. Hui
-
Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
Patent number: 8263558Abstract: The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays.Type: GrantFiled: November 30, 2006Date of Patent: September 11, 2012Assignees: Abbott Laboratories, Abbott GmbH & Co. KGInventors: Thomas F. Holzman, John E. Harlan, Rohinton P. Edalji, Edward T. Olejniczak, Ana Pereda-Lopez, Boris Labkovsky, Liping Yu, Heinz Hillen, Stefan Barghorn, Ulrich M. Ebert -
Patent number: 8263363Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.Type: GrantFiled: October 5, 2010Date of Patent: September 11, 2012Assignee: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr.
-
Publication number: 20120225079Abstract: An antigenic composition comprises at least one antigen, wherein said at least one antigen comprises at least part of a protein selected from EndoSe of Streptococcus equi subsp. Equi, EndoSz of Streptococcus equi subsp. zooepidemicus, and Endo S of Streptococcus pyogenes, and wherein said at least part of said protein comprises at least one antigenic epitope. A vaccine composition comprising the antigenic composition as immunizing component, methods for producing the antigeninc composition and the vaccine composition, use of the vaccine composition for prophylactic and therapeutic treatment, and an antibody preparation comprising monoclonal or polyclonal antibodies specific for an antigen or antigens of the antigenic composition are also disclosed.Type: ApplicationFiled: November 11, 2010Publication date: September 6, 2012Applicant: INTERVACC ABInventors: Bengt Guss, Lars Frykberg, Jan-Ingmar Flock, Margareta Flock
-
Publication number: 20120225454Abstract: The present invention relates to synthetic operons. In particular, the present invention relates to a synthetic operon for integration into a bacterial chromosome of a bacterium comprising a promoter operably-linked to at least two genes, wherein at least one gene is a gene of interest and at least one gene is a gene essential to said bacterium.Type: ApplicationFiled: June 25, 2010Publication date: September 6, 2012Applicant: ONDEK PTY LTDInventors: Mohammed Benghezal, Yakhya Dieye, Carola Schwann, Miriam Sehnal, Alma Fulurija, Barry J. Marshall
-
Publication number: 20120219580Abstract: The present invention relates to a method for producing transgenic plants, which involves producing hemagglutinin proteins of the H5N1 virus using a plant transformation recombinant vector, wherein said vector can express hemagglutinin proteins of the H5N1 virus, the highly pathogenic avian influenza virus, and transport proteins expressed in plants to the endoplasmic reticulum and enable the retention of the proteins in the endoplasmic reticulum to enable glycosylation required for antigen activity. The present invention also relates to a method for the mass production of hemagglutinin proteins of the antigenic H5N1 virus from transgenic plants or a vaccine composition for the avian influenza virus comprising the transgenic plants or the hemagglutinin proteins produced from the plants. The transgenic plants can be used as edible vaccines, antigenic hemagglutinin proteins produced can be used as protein vaccines for the H5N1 avian influenza virus, or as diagnostic reagents for avian influenza virus infection.Type: ApplicationFiled: October 6, 2010Publication date: August 30, 2012Applicant: Helix, Co., LimitedInventors: In Hwan Hwang, Eun Ju Sohn, Eun Hye Kwon, Yun Jeong Na, Eun Hyun Jeon, Se Jin Im, Ki Seok Park, Young Chul Sung
-
Publication number: 20120219577Abstract: The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field isolates wherein the antigen sequences are closely related to the these consensus sequences. Advantageously, the present invention relates to HIV-1 Clade A transgenes that are derived from such sequences, and that encode either HIV-1 Clade A Gag, Pol (RT and Int), and Nef (collectively “GRIN”), HIV-1 Clade A Gag, RT, and Nef (collectively “GRN”), or HIV-1 Clade A Env. The invention also relates to vectors containing such transgenes, including adenovirus vectors containing such transgenes. The invention also relates to immunogenic compositions comprising the HIV-1 Clade A antigens, nucleotide sequences, vectors, or transgenes of the invention, and to methods of generating an immune response against HIV in a subject by administering an effective amount of such immunogenic compositions.Type: ApplicationFiled: February 17, 2012Publication date: August 30, 2012Inventors: Kalpana GUPTA, Nicholas Jackson
-
Patent number: 8252289Abstract: The invention relates to N protein-protein of interest fusion proteins, optionally in the form of soluble N protein-protein of interest/P protein complexes, the N and P proteins being proteins of a virus of the Paramyxoviridae family. When the protein of interest is an antigen, the invention relates also to vaccinal compositions and diagnostic reagents comprising those N protein-antigen fusion proteins or those N protein-antigen/P protein complexes. The N protein-protein of interest fusion protein can also be used as a “vector” for transporting into cells therapeutic molecules of interest, such as antivirals or anticancer agents.Type: GrantFiled: April 18, 2007Date of Patent: August 28, 2012Assignee: Institut National de la Recherche Agronomique (INRA)Inventors: Jean-François Eleouët, Sabine Riffault
-
Patent number: 8246964Abstract: Antigenic protein fragments of Streptococcus pneumoniae to be used for the preparation of a medicament for the prevention and the treatment of bacterial infections and a method for the detection thereof, and related compositions using said epitopes, are disclosed.Type: GrantFiled: March 17, 2009Date of Patent: August 21, 2012Assignees: Universita' Degli Studi di SienaInventors: Concetta Beninati, Franco Felici, Marco Oggioni, Gianni Pozzi, Susanna Ricci
-
Publication number: 20120208176Abstract: The present invention relates to a new method to determine the presence of antibodies to a pathogen in a serological sample using a new detection reagent which comprises at least two and preferably at least four copies of an antigen from the pathogen and a detectable marker. The present invention also relates to a new detection reagent which consists of at least two and preferably at least four antigenic peptides in a complex with a detectable marker via interacting multimerization domains upon both the antigenic peptides and detectable marker.Type: ApplicationFiled: July 6, 2010Publication date: August 16, 2012Applicant: INSTITUT PASTEURInventors: Hugues Bedouelle, Philippe Dussart, Nora Zidane, Laetitia Bremand
-
Patent number: 8241871Abstract: Cloning and expression of genes encoding C. parvum antigenic polypeptides are described as are antibodies that recognize epitopes on these polypeptides. The antigenic polypeptides and antibodies thereto can be used in therapeutic compositions for the prevention and treatment of C. parvum infections, as well as in diagnostic methods for determining the presence of C. parvum infections.Type: GrantFiled: October 29, 2010Date of Patent: August 14, 2012Assignee: University of ManitobaInventor: J. Neil Simonsen
-
Publication number: 20120201846Abstract: The present invention relates to polymer particles and uses thereof. In particular the present invention relates to functionalised polymer particles, processes of production and uses thereof in eliciting a cell-mediated immune response and in the treatment or prevention of diseases or conditions including those caused by intracellular pathogens.Type: ApplicationFiled: July 29, 2010Publication date: August 9, 2012Inventors: Bernd Helmut Adam Rehm, Natalie Anne Parlane, David Neil Wedlock, Bryce Malcolm Buddle
-
Publication number: 20120201825Abstract: The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.Type: ApplicationFiled: April 19, 2011Publication date: August 9, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEURInventors: Frederic TANGY, Marianne Lucas-Hourani, Erika Navarro-Sanchez, Marie-Pascale Frenkiel, Hugues Bedouelle, Chantal Combredet, Philippe Despres
-
Publication number: 20120202249Abstract: The present invention relates to constructs and methods for the production of recombinant proteins, viruses, and viral vaccines in heterologous culture systems by expressing intact genes or viral genomes under the control of a pantropic promoter in a culture system that is not considered a host to the virus so produced. The promoter/viral genome constructs are inserted into a baculovirus and expressed in mammalian non-host cells for the baculovirus.Type: ApplicationFiled: April 8, 2010Publication date: August 9, 2012Inventor: Arun K. Dhar
-
Publication number: 20120195962Abstract: The present invention includes fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing such fusion peptides, virosomes comprising such fusion peptides, and uses of such fusion peptides or virosomes for the prevention, treatment or amelioration of a cancer characterized by expression or over-expression of the Her2/neu protein.Type: ApplicationFiled: August 18, 2010Publication date: August 2, 2012Applicant: PEVION BIOTECH AGInventors: Andreas Kammer, Mario Amacker, Rinaldo Zurbriggen
-
Publication number: 20120189661Abstract: The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal.Type: ApplicationFiled: October 7, 2010Publication date: July 26, 2012Inventor: Francis E. Nano
-
Publication number: 20120189662Abstract: The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M. bovis BCG::RD1 or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer.Type: ApplicationFiled: September 21, 2010Publication date: July 26, 2012Inventors: Stewart Cole, Alexander S. Pym, Roland Brosch, Priscille Brodin, Laleh Majlessi, Caroline Demangel, Claude LeClerc
-
Publication number: 20120190067Abstract: The present invention relates to methods for producing a biological substance, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the biological substance, wherein the fungal host cell comprises a first nucleic acid sequence encoding the biological substance operably linked to a second nucleic acid sequence comprising a promoter variant selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12; and a subsequence thereof; and hybrid and tandem promoters thereof; and (b) isolating the biological substance from the cultivation medium. The present invention also relates to the isolated promoter variants and to constructs, vectors, and fungal host cells comprising the promoter variants operably linked to nucleic acid sequences encoding biological substances.Type: ApplicationFiled: March 19, 2012Publication date: July 26, 2012Applicant: Novozymes, Inc.Inventors: Debbie Yaver, Peter Nham
-
Publication number: 20120183979Abstract: Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in Anaplasma phagocytophilum. Such recombinant protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as kits for ELISA is also disclosed.Type: ApplicationFiled: March 13, 2012Publication date: July 19, 2012Applicant: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.Inventors: John G. Hoey, Denise P. Dimitrov, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
-
Publication number: 20120183964Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: March 29, 2012Publication date: July 19, 2012Applicant: Schering CorporationInventor: J. Fernando Bazan
-
Patent number: 8216589Abstract: The present invention relates to an HBV vaccine comprising an entire hepatitis B surface antigen of L protein, M protein and S protein, in which the produced antigens form virus-like particles, and a multi-antigen vaccine further comprising an HBV core antigen in addition to the entire surface antigen, and a method for preparing the same. The vaccines provide various epitopes and have excellent immunogenicity to induce a strong humoral immune response as well as a cell-mediated immune response.Type: GrantFiled: January 28, 2008Date of Patent: July 10, 2012Assignee: Dobeel CorporationInventors: Jung Sun Yum, Byung Cheol Ahn, Hyun Jin Jo, Dong Yeon Kim, Joo Youn Lee, Ki Hyun Kim, Jae Seung Yoon, Hong Mo Moon
-
Publication number: 20120171214Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.Type: ApplicationFiled: March 14, 2012Publication date: July 5, 2012Applicant: ABSYNTH BIOLOGICS LIMITEDInventors: Simon J. FOSTER, Jorge GARCIA-LARA
-
Publication number: 20120164687Abstract: The present invention relates to a new bacterial strain of Samonella enterica serovar Typhimurium VNP20009 deposited in the Polish Collection of Microorganisms under access no. B/00024 and its us in the production of a vaccine, especially an anti-cancer vaccine. The present invention also relates to a method of obtaining a therapeutic vaccine vector, characterized in that a genetic modification is introduced into the vector strain specific to cancer cells, resulting in the delayed over expression of a gene encoding a protein responsible for the invasive ability of this strain.Type: ApplicationFiled: February 23, 2010Publication date: June 28, 2012Inventors: Michal Bereta, Joanna Bereta, Paulina Chorobik
-
Patent number: 8206950Abstract: Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety.Type: GrantFiled: November 22, 2008Date of Patent: June 26, 2012Assignee: Animal Technology Institute TaiwanInventors: Chao-Wei Liao, Chung-Nan Weng, Hsiu-Kang Chang
-
Publication number: 20120156723Abstract: The disclosure relates to an oligosaccharyltransferase polypeptide and the production of glycosylated recombinant protein in a microbial host cell; and including vaccines comprising glycosylated recombinant antigens.Type: ApplicationFiled: September 3, 2010Publication date: June 21, 2012Inventors: Brendan Wren, Rebecca Langdon
-
Patent number: 8202723Abstract: Described are vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Also described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.Type: GrantFiled: May 31, 2011Date of Patent: June 19, 2012Assignees: Crucell Holland B.V., Aeras Global TB Vaccine FoundationInventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Rado{hacek over (s)}evic
-
Publication number: 20120148601Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: ApplicationFiled: November 28, 2011Publication date: June 14, 2012Inventors: ROBERT G. ULRICH, Mark A. Olson, Sina Bavari
-
Publication number: 20120148618Abstract: Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.Type: ApplicationFiled: February 6, 2012Publication date: June 14, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: MAURIZIO COMANDUCCI, MARIAGRAZIA PIZZA
-
Patent number: 8198424Abstract: The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of making a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against Yersinia pestis.Type: GrantFiled: July 15, 2010Date of Patent: June 12, 2012Assignee: Wake Forest University Health SciencesInventors: Steven B. Mizel, Anna Nichole Honko
-
Publication number: 20120142055Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.Type: ApplicationFiled: December 30, 2011Publication date: June 7, 2012Inventors: Russell DeKelver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
-
Publication number: 20120142054Abstract: A polynucleotide base sequence represented by SEQ ID NO: 22, a vector containing the polynucleotide and a method of preparing a small round structure virus (SRSV) virus-like particle in insect cells with vector.Type: ApplicationFiled: October 6, 2011Publication date: June 7, 2012Applicants: DENKA SEIKEN CO. LTD., JP AS REP BY DIR-GEN NATL INST OF INF DISInventors: Naokazu TAKEDA, Katsuro Natori, Tatsuo Miyamura, Kunio Kamata, Toshinori Sato, Seiya Sato
-
Publication number: 20120141487Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a Moraxella catarrhalis (Meat) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Moraxella catarrhalis species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell which expresses such antigen. More specifically, such antigens are produced by or associated with bacterial infections caused by Moraxella catarrhalis.Type: ApplicationFiled: May 28, 2010Publication date: June 7, 2012Applicant: Intercell AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Julia Flor, Birgit Noiges, Wolfgang Schueler, Ulrike Schirmer, Verena Salletmayer, Mario Aistleithner, Stefan Seidel, Martin Oleksiewicz
-
Publication number: 20120128709Abstract: The invention provides auto-inducible systems for expressing recombinant proteins of interest which take advantage of elements of quorum sensing (QS) systems of certain bacteria. These systems can be used to produce commercial quantities of proteins such as antigens, which can be used to prepare pharmaceutical compositions.Type: ApplicationFiled: May 28, 2010Publication date: May 24, 2012Inventors: Erwin Swennen, Salvatore Nocadello
-
Publication number: 20120121628Abstract: This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide.Type: ApplicationFiled: November 15, 2011Publication date: May 17, 2012Applicant: National Health Research InstitutesInventors: Chih-Hsiang Leng, Chi-Ling Tseng, Hsueh-Hung Liu, Shih-Jen Liu, Hsin-Wei Chen, Pele Choi-Sing Chong
-
Publication number: 20120121630Abstract: The present invention provides Herpes Simplex Virus (HSV) gD, gC, gB and/or gE recombinant glycoproteins having a particular pre-selected N-linked glycosylation pattern as the predominant N-glycoform. The present invention also provides methods of producing these recombinant glycoproteins in yeast, preferably Pichia pastoris, which may be glycoengineered to provide particular glycosylation patterns. The present invention further provides vaccines comprising gD and gC, and optionally gB and/or gE, at least one of which has a particular pre-selected N-linked glycosylation pattern as the predominant N-glycoform. The recombinant glycoproteins are produced by a method which, in one embodiment, comprises transforming a yeast of the genus Pichia with an expression vector containing a DNA encoding an HSV glycoprotein, which is under regulation of a promoter functional in a yeast of the genus Pichia, culturing the yeast in a medium, and recovering the recombinant glycoprotein from the obtained culture.Type: ApplicationFiled: July 21, 2010Publication date: May 17, 2012Inventors: Janine T. Bryan, John W. Ballet, Jessica A. Flynn, Danilo R. Casimiro, Robert C. Davidson, Victoria Copeland, Sandra E. Rios, Byung-Kwon Choi, Stefan Wildt
-
Publication number: 20120115156Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.Type: ApplicationFiled: March 18, 2011Publication date: May 10, 2012Inventors: Shirley Longacre, Hannah Polson, Ronald Perraut, Faridabano Nato
-
Publication number: 20120107301Abstract: Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity.Type: ApplicationFiled: August 24, 2011Publication date: May 3, 2012Applicant: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Naveen Dakappagari
-
Publication number: 20120107339Abstract: Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of N. meningitidis, and methods of use, are provided.Type: ApplicationFiled: March 9, 2009Publication date: May 3, 2012Inventors: Dan M. Granoff, Peter Beernink, Jo Anne Welsch
-
Publication number: 20120100169Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.Type: ApplicationFiled: October 20, 2009Publication date: April 26, 2012Applicant: Eyegene Inc.Inventors: Hong-Jin Kim, Na Gyong Lee, Yang-Je Cho, Jin-Wook Jang, Hyoung Jin Kim, Kwang Sung Kim
-
Publication number: 20120100143Abstract: Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the Leptospira OMPs can be used to create, manufacture or improve vaccines. Vaccines, including but not limited to DNA vaccines, recombinant vaccines, and T-cell epitope vaccines based on the foregoing OMPs are also provided. Methods for producing such vaccines are also provided. Also provided are methods for using Leptospira OMP genes, proteins and antibodies for therapeutic treatment and serological diagnosis techniques.Type: ApplicationFiled: September 22, 2008Publication date: April 26, 2012Inventor: Yung-Fu Chang